title: [Expert opinion about the use of transdermic oxybutynin in Spain for the treatment of adult overactive bladder.]
abstract: OBJECTIVE
  To define the different characteristics of transdermal oxybutynin (TO) for the treatment of overactive bladder in adults, to know the barriers for the use of this drug and to establish proposals to minimize these barriers.
  
  
  METHODS
  Local sessions were held with 111 urologists from all over the country divided into 12 sessions. They were moderated by a brainstorming technique led by an external consultant.
  
  
  RESULTS
  75% of experts believe that tolerability and clinical efficacy (50%) are the most important attributes to choose this formulation, being the lack of scientific publications the least valued (12%). These opinions were based on their own clinical experience with TO or on scientific publications, without establishing comparison with other treatment options. The main barriers would be administrative obstacles (84%), difficulty in its use (54%) and the lack/rejection of the transdermal administration by the patient (33%). Actions were proposed to correct the 8 most significant barriers, such as better training for specialists (both Urology and other specialties) and for patients, creating informative materials to reinforce health education in managing patches, generating greater volume of scientific evidence to support their use in overactive bladder and clearly identifying the profile of patients who will benefit most from this therapeutic strategy.
  
  
  CONCLUSIONS
  Although oxybutynin has been standard treatment of overactive bladder in recent years the conclusion of this working group is that its new transdermal formulation offers a better-tolerated alternative for patients, and, therefore the necessary tools to generate more evidence should be implemented to increase the proper use among specialists and patients.
authors.affiliation: Servicio de Urología. Complejo Hospitalario de Ourense. España.
authors.forename: Carlos
authors.initials: C
authors.lastname: Müller-Arteaga
authors.affiliation: Sección de Urología Reconstructiva y Funcional. Servicio de Urología. Hospital Universitario y Politécnico La Fe, Valencia. España.
authors.forename: Salvador
authors.initials: S
authors.lastname: Arlandis Guzmán
authors.affiliation: Servicio de Urología. Hospital Universitario de Salamanca. España.
authors.forename: María Fernanda
authors.initials: MF
authors.lastname: Lorenzo Gómez
authors.affiliation: Unidad de Urología Funcional y Femenina. Fundació Puigvert. Barcelona. España.
authors.forename: Carlos
authors.initials: C
authors.lastname: Errando-Smet
authors.affiliation: Servicio de Urología. Hospital Universitario Fundación Jiménez Díaz. Madrid. Hospital Universitario Infanta Elena, Valdemoro, Madrid. España.
authors.forename: Raquel
authors.initials: R
authors.lastname: González López
authors.affiliation: Servicio de Urología. Hospital Universitario Infanta Leonor, Madrid. España.
authors.forename: Javier
authors.initials: J
authors.lastname: Cambronero Santos
authors.affiliation: Servicio de Urología. Hospital de Valdecilla, Santander. España.
authors.forename: José Luis
authors.initials: JL
authors.lastname: Gutiérrez Baños
authors.affiliation: Servicio de Urología. Hospital General de Elda, Alicante. España.
authors.forename: Manuel
authors.initials: M
authors.lastname: Sánchez Marcos
authors.affiliation: Servicio de Urología. Hospital Virgen Macarena, Sevilla. España.
authors.forename: Antonio
authors.initials: A
authors.lastname: Ortiz Gamiz
authors.affiliation: Servicio de Urología. Hospital de Poniente, El Ejido, Almería. España.
authors.forename: Sergio
authors.initials: S
authors.lastname: Merino Salas
authors.affiliation: Servicio de Urología. Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona. España.
authors.forename: Roberto
authors.initials: R
authors.lastname: Martínez Rodriguez
authors.affiliation: Servicio de Urología. Hospital de Cruces, Baracaldo, Vizcaya. España.
authors.forename: Ivan
authors.initials: I
authors.lastname: Olano Grasa
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D006801:Humans; D008333:Mandelic Acids / Q000008:administration & dosage*; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic; D013030:Spain; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D008333:Mandelic Acids; D018727:Muscarinic Antagonists; C005419:oxybutynin